International Cancer Conference Journal最新文献_第8页

ATM mutation in aggressive uterine adenosarcoma in which systemic chemotherapies had remarkable effects. 全身化疗效果显著的侵袭性子宫腺肉瘤中的 ATM 突变。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-12 eCollection Date: 2023-04-01 DOI: 10.1007/s13691-022-00591-6

Misaki Koyama, Ken Yamaguchi, Yoshitsugu Chigusa, Koji Yamanoi, Mana Taki, Masumi Sunada, Akihito Horie, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai

引用次数: 0

A case of advanced breast cancer with Gitelman syndrome. 一例晚期乳腺癌合并吉特曼综合征。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-04 eCollection Date: 2023-04-01 DOI: 10.1007/s13691-022-00593-4

Yuko Tanaka, Miyuki Muramatsu, Yoshihiro Miyauchi, Yoshio Suzuki, Tamaki Morohashi, Kandai Nozu

引用次数: 0

Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report. 奥拉帕尼治疗 BRCA1 基因突变的神经内分泌性前列腺癌后的间质性肺炎：病例报告。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-03 eCollection Date: 2023-04-01 DOI: 10.1007/s13691-022-00592-5

Masashi Kaitsumaru, Masaki Shiota, Dai Takamatsu, Leandro Blas, Takashi Matsumoto, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto

引用次数: 0

Lenvatinib-refractory thymic mucinous carcinoma with PIK3CA mutation. lenvatinib难治性胸腺粘液癌伴PIK3CA突变。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-01 DOI: 10.1007/s13691-022-00573-8

Akihiro Tsukaguchi, Shoichi Ihara, Hironao Yasuoka, Seigo Minami

{"title":"Lenvatinib-refractory thymic mucinous carcinoma with PIK3CA mutation.","authors":"Akihiro Tsukaguchi, Shoichi Ihara, Hironao Yasuoka, Seigo Minami","doi":"10.1007/s13691-022-00573-8","DOIUrl":"https://doi.org/10.1007/s13691-022-00573-8","url":null,"abstract":"Mucinous adenocarcinoma, a very rare type of thymic carcinoma, is aggressive and has a poor prognosis. The optimal treatment for advanced thymic mucinous adenocarcinoma has not yet been established because of its rarity. An oral multi-tyrosine kinase inhibitor, lenvatinib, was approved for treatment of thymic carcinoma in March 2021 in Japan. However, to the best of our knowledge, there are no published reports concerning lenvatinib for thymic mucinous adenocarcinoma. Herein, we report a 39-year-old woman who presented with a 70 mm multilocular cystic tumor in her left anterior mediastinum and a massive pericardial effusion. We diagnosed a Masaoka stage IVb thymic mucinous adenocarcinoma with multiple metastases to the liver and bones, and pericardial dissemination on the basis of the pathologic findings on examination of a video-assisted thoracoscopic tumor biopsy and radiological examinations. She received paclitaxel-carboplatin-based chemotherapy, but developed a left cerebellar metastasis. Second-line chemotherapy with lenvatinib failed to suppress the tumor. She died of cancer progression 5 months after presentation. Here, we report what we believe to be the first case of a thymic mucinous adenocarcinoma treated with lenvatinib. Our patient's thymic mucinous adenocarcinoma was refractory to both cytotoxic chemotherapy and lenvatinib. Using next-generation sequencing, we identified phosphatidylinositol 3-kinase catalytic subunit alpha mutation in the tumor. We suspected an association between this mutation and resistance to lenvatinib. We therefore recommend performing next-generation sequencing when considering introduction of lenvatinib for thymic mucinous adenocarcinoma. A surgical procedure may be necessary for accurate diagnosis and genetic analysis of this histological tumor type.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"36-40"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807735/pdf/13691_2022_Article_573.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10037866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid-onset paraneoplastic cerebellar degeneration successfully treated by radiotherapy and tumorectomy. 快速发作的副肿瘤小脑变性经放疗和肿瘤切除术成功治疗。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-01 DOI: 10.1007/s13691-022-00569-4

Philippe Westerlinck, Nicolas Janin, Philippe Coucke

{"title":"Rapid-onset paraneoplastic cerebellar degeneration successfully treated by radiotherapy and tumorectomy.","authors":"Philippe Westerlinck, Nicolas Janin, Philippe Coucke","doi":"10.1007/s13691-022-00569-4","DOIUrl":"https://doi.org/10.1007/s13691-022-00569-4","url":null,"abstract":"We report the first-ever documented case of successful treatment of paraneoplastic cerebellar degeneration (PCD) with radiotherapy. A 31-year-old female presented with rapidly progressing neurological symptoms, which were revealed to be due to PCD secondary to an undiagnosed breast cancer. The cancer responded well to chemotherapy, but her neurological status continued to deteriorate, eventually progressing to complete expressive aphasia and dyssynergia with paraparesis. Due to the extraordinarily rapid progression of the disorder, a treatment with tumorectomy and radiotherapy of the whole brain was performed. This proved to be very successful, with a complete stop of the deterioration of symptoms after treatment and with a significant neurologic improvement in the following months. This case indicates that there may be a place for radiotherapy in the treatment of PCD. Current treatment options have proven insufficient and no guidelines for treatment currently exist. As such, the disorder remains associated with a very poor prognosis and often entails permanent loss of function. Radiation, with its known immunosuppressive effect and non-stochastic effects on the nervous system at the proper doses, might therefore be a valid option. However, we should note that it was in this instance combined with a removal of the primary tumor and as such, its individual efficacy cannot be considered proven.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"19-23"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807696/pdf/13691_2022_Article_569.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Systemic chemotherapy for unresectable or recurrent primary thymic adenocarcinoma of enteric type. 不可切除或复发的肠型原发性胸腺癌的全身化疗。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-01 DOI: 10.1007/s13691-022-00575-6

Xiaofang Gao

引用次数: 0

Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy associated with gastric cancer and response to immediate chemotherapy. 胃癌相关肺肿瘤血栓性微血管病变的死前诊断及对即刻化疗的反应。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-01 DOI: 10.1007/s13691-022-00566-7

Kohei Fujita, Takeshi Omori, Hisashi Hara, Naoki Shinno, Masaaki Yamamoto, Takashi Kanemura, Tomohira Takeoka, Takahito Sugase, Hiroshi Miyata, Masayuki Ohue, Masato Sakon

{"title":"Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy associated with gastric cancer and response to immediate chemotherapy.","authors":"Kohei Fujita, Takeshi Omori, Hisashi Hara, Naoki Shinno, Masaaki Yamamoto, Takashi Kanemura, Tomohira Takeoka, Takahito Sugase, Hiroshi Miyata, Masayuki Ohue, Masato Sakon","doi":"10.1007/s13691-022-00566-7","DOIUrl":"https://doi.org/10.1007/s13691-022-00566-7","url":null,"abstract":"Pulmonary tumor thrombotic microangiopathy is a rare and fatal complication of cancer that features widespread tumor cell-derived embolisms in the small arteries and arterioles of the lung and is often associated with thrombus formation. We describe the case of a 43-year-old woman who was hospitalized with cough and respiratory distress that lasted for 2 months. Computed tomography findings demonstrated multiple areas of interlobular septal thickening and ground-glass opacities in both lungs. Transthoracic echocardiography demonstrated a D-shaped left ventricle suggesting right heart overload, and pulmonary blood flow scintigraphy revealed multiple small, peripheral, and patchy areas of reduced blood flow. Upper gastrointestinal endoscopy revealed a signet-ring carcinoma. The patient was diagnosed with pulmonary tumor thrombotic microangiopathy based on her clinical presentation and treatment with tegafur, gimeracil oteracil potassium, oxaliplatin, and an anticoagulant was initiated on the 3rd day after admission. The symptoms improved rapidly after treatment initiation. The patient was discharged 28 days after initiation of chemotherapy without the need for supplemental oxygen. This case suggests that the immediate use of chemotherapy and anticoagulants for treating pulmonary tumor thrombotic microangiopathy may improve patient survival.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"1-6"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807729/pdf/13691_2022_Article_566.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9890984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer. 贝伐单抗联合多西他赛-卡铂治疗卵巢癌皮肤脱屑5例

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-01 DOI: 10.1007/s13691-022-00576-5

Megumi Tokunaga, Shuichi Nawata, Takayuki Komoto, Rei Mathuura, Daisuke Ichikura, Toru Watanabe, Tadanori Sasaki

{"title":"Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer.","authors":"Megumi Tokunaga, Shuichi Nawata, Takayuki Komoto, Rei Mathuura, Daisuke Ichikura, Toru Watanabe, Tadanori Sasaki","doi":"10.1007/s13691-022-00576-5","DOIUrl":"https://doi.org/10.1007/s13691-022-00576-5","url":null,"abstract":"The standard of care for ovarian cancer chemotherapy is paclitaxel-carboplatin. In Stage III and Stage IV patients, the addition of bevacizumab has been reported to be effective, and bevacizumab combined with paclitaxel-carboplatin and bevacizumab combined with docetaxel-carboplatin are used. Patients who received bevacizumab combined with docetaxel-carboplatin experienced a high incidence of skin hardening followed by peeling. In patients treated with bevacizumab combined with docetaxel-carboplatin, we experienced a high incidence of post-sclerotic peeling of the skin, a symptom that is rarely seen with paclitaxel-carboplatin (TC), docetaxel-carboplatin (DC), or bevacizumab combined with paclitaxel-carboplatin, and has been reported in a few cases. Therefore, we investigated the actual situation of skin desquamation caused by bevacizumab combined with docetaxel-carboplatin. Thirty-one patients were included in the study, and their age (mean ± SD) was 62.9 ± 9.0. The breakdown of treatment was as follows: TC in nine patients, bevacizumab combined with paclitaxel-carboplatin in ten patients, DC in six patients, and bevacizumab combined with docetaxel-carboplatin in six patients. No number of patients with TC or bevacizumab combined with paclitaxel-carboplatin showed skin desquamation. One for DC, and five for bevacizumab combined with docetaxel-carboplatin. The five patients treated with bevacizumab combined with docetaxel-carboplatin improved with topical steroids and moisturizers, but symptoms repeatedly appeared after each course. Skin desquamation was more frequent in bevacizumab combined with docetaxel-carboplatin.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"49-52"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Solitary pulmonary capillary hemangioma mimicking a preinvasive malignant lesion in an asymptomatic middle-aged female patient. 一例无症状中年女性患者的孤立性肺毛细血管瘤表现为侵袭前恶性病变。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-01 DOI: 10.1007/s13691-022-00570-x

Yasuyuki Kanamoto, Hitoshi Dejima, Yuichi Saito, Toshihiro Haga, Tomohiro Watanabe, Yoshikane Yamauchi, Yuko Sasajima, Koji Saito, Masafumi Kawamura, Yukinori Sakao

{"title":"Solitary pulmonary capillary hemangioma mimicking a preinvasive malignant lesion in an asymptomatic middle-aged female patient.","authors":"Yasuyuki Kanamoto, Hitoshi Dejima, Yuichi Saito, Toshihiro Haga, Tomohiro Watanabe, Yoshikane Yamauchi, Yuko Sasajima, Koji Saito, Masafumi Kawamura, Yukinori Sakao","doi":"10.1007/s13691-022-00570-x","DOIUrl":"https://doi.org/10.1007/s13691-022-00570-x","url":null,"abstract":"Pulmonary capillary hemangiomatosis (PCH) is a rare disease characterized by a proliferation of capillaries in the alveolar septa, bronchial and venous walls, pleura, and regional lymph nodes. However, the etiology of the disease remains unknown due to its rarity. Therefore, we present a case of a solitary PCH lesion without symptoms in a 38-year-old female patient. According to computed tomography, she was diagnosed with lung carcinoma, indicated by a tiny nodule with ground-glass opacity detected in her right upper lung. However, no other lesions were detected on systemic examination. Consequently, partial lung resection was conducted, since the lesion was suspected of lung adenocarcinoma. Pathologic results showed that the thick alveolar septa were caused by capillary growth without cellular atypia and hardly any infiltration of inflammatory cells. Finally, we diagnosed the pulmonary lesion as PCH, although solitary PCH has previously been reported in a few case reports. Therefore, further case studies are essential to clarify the causes of PCH.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"14-18"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807707/pdf/13691_2022_Article_570.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9926140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perianal Bowen's disease treated with radiotherapy preserving anal function with a unique skin reaction considered as 'tumoritis'. 用放射疗法治疗肛周鲍文病，保留肛门功能，有独特的皮肤反应，被认为是“肿瘤炎”。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-01-01 DOI: 10.1007/s13691-022-00574-7

Takahiro Iwai, Toshiyuki Imagumbai, Shun Okabayashi, Ryo Ashida, Takamasa Mitsuyoshi, Yukimasa Tai, Toshihiko Matsumoto, Daisuke Yamashita, Tohru Nagano, Masaki Kokubo

引用次数: 0